A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.
Saved in:
| Title: | A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors. |
|---|---|
| Authors: | Siu LL; Princess Margaret Cancer Centre, University Health Network, University of Toronto, 700 University Avenue, Suite 7-624, Toronto, M5G 1Z5, Canada. lillian.siu@uhn.ca., Hong DS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Döcke WD; Bayer AG, Berlin, Germany., Tetzner R; Bayer AG, Berlin, Germany., Trautwein M; Bayer AG, Wuppertal, Germany., Phelps C; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA., Willuda J; Bayer AG, Berlin, Germany., Yu XQ; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA., Nogai H; Bayer Consumer Care, Basel, Switzerland.; Ryvu Therapeutics, Krakow, Poland., Johnson M; Drug Development Unit, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA., Goh BC; National University Cancer Institute and National University Hospital and Cancer Science Institute, National University of Singapore, Singapore, Singapore. |
| Source: | Targeted oncology [Target Oncol] 2025 Jul; Vol. 20 (4), pp. 637-649. Date of Electronic Publication: 2025 Jun 04. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1776-260X |
|---|---|
| DOI: | 10.1007/s11523-025-01154-4 |
